OBJECTIVE: To estimate the prevalence of musculoskeletal (MSK) disorders and to describe predicting variables associated with rheumatic diseases in 5 regions of México. METHODS: This was a cross-sectional, community-based study performed in 5 regions in México. The methodology followed the guidelines proposed by the Community Oriented Program for the Control of the Rheumatic Diseases (COPCORD). A standardized methodology was used at all sites, with trained personnel following a common protocol of interviewing adult subjects in their household. A "positive case" was defined as an individual with nontraumatic MSK pain of > 1 on a visual analog pain scale (0 to 10) during the last 7 days. All positive cases were referred to internists or rheumatologists for further clinical evaluation, diagnosis, and proper treatment. RESULTS: The study included 19,213 individuals; 11,602 (68.8%) were female, and their mean age was 42.8 (SD 17.9) years. The prevalence of MSK pain was 25.5%, but significant variations (7.1% to 43.5%) across geographical regions occurred. The prevalence of osteoarthritis was 10.5%, back pain 5.8%, rheumatic regional pain syndromes 3.8%, rheumatoid arthritis 1.6%, fibromyalgia 0.7%, and gout 0.3%. The prevalence of MSK manifestations was associated with older age and female gender. CONCLUSION: The prevalence of MSK pain in our study was 25.5%. Geographic variations in the prevalence of MSK pain and specific diagnoses suggested a role for geographic factors in the prevalence of rheumatic diseases.
OBJECTIVE: To estimate the prevalence of musculoskeletal (MSK) disorders and to describe predicting variables associated with rheumatic diseases in 5 regions of México. METHODS: This was a cross-sectional, community-based study performed in 5 regions in México. The methodology followed the guidelines proposed by the Community Oriented Program for the Control of the Rheumatic Diseases (COPCORD). A standardized methodology was used at all sites, with trained personnel following a common protocol of interviewing adult subjects in their household. A "positive case" was defined as an individual with nontraumatic MSK pain of > 1 on a visual analog pain scale (0 to 10) during the last 7 days. All positive cases were referred to internists or rheumatologists for further clinical evaluation, diagnosis, and proper treatment. RESULTS: The study included 19,213 individuals; 11,602 (68.8%) were female, and their mean age was 42.8 (SD 17.9) years. The prevalence of MSK pain was 25.5%, but significant variations (7.1% to 43.5%) across geographical regions occurred. The prevalence of osteoarthritis was 10.5%, back pain 5.8%, rheumatic regional pain syndromes 3.8%, rheumatoid arthritis 1.6%, fibromyalgia 0.7%, and gout 0.3%. The prevalence of MSK manifestations was associated with older age and female gender. CONCLUSION: The prevalence of MSK pain in our study was 25.5%. Geographic variations in the prevalence of MSK pain and specific diagnoses suggested a role for geographic factors in the prevalence of rheumatic diseases.
Authors: Javier Fernández-Torres; Gabriela Angélica Martínez-Nava; Yessica Zamudio-Cuevas; Karina Martínez-Flores; María Concepción Gutiérrez-Ruíz; Luis Enrique Gómez-Quiroz; Daniela Garrido-Rodríguez; José Francisco Muñoz-Valle; Edith Oregón-Romero; Carlos Lozada; Denise Clavijo Cornejo; Carlos Pineda; Alberto López-Reyes Journal: Clin Rheumatol Date: 2019-06-25 Impact factor: 2.980
Authors: José M A Wijnands; Wolfgang Viechtbauer; Kristof Thevissen; Ilja C W Arts; Pieter C Dagnelie; Coen D A Stehouwer; Sjef van der Linden; Annelies Boonen Journal: Eur J Epidemiol Date: 2014-07-27 Impact factor: 8.082
Authors: Uhunmwangho U Courage; Dungwom P Stephen; Imoh C Lucius; Charles Ani; Agbaji O Oche; Agaba I Emmanuel; Adelowo O Olufemi Journal: Clin Rheumatol Date: 2017-04-26 Impact factor: 2.980
Authors: S Sam Lim; A Rana Bayakly; Charles G Helmick; Caroline Gordon; Kirk A Easley; Cristina Drenkard Journal: Arthritis Rheumatol Date: 2014-02 Impact factor: 10.995
Authors: Jacqueline Rodriguez-Amado; Jose Moreno-Montoya; Jose Alvarez-Nemegyei; Maria Victoria Goycochea-Robles; Luz Helena Sanin; Ruben Burgos-Vargas; Mario Humberto Cardiel; Mario Alberto Garza-Elizondo; Marco Maradiaga; Ingris Pelaez-Ballestas Journal: Clin Rheumatol Date: 2014-09-18 Impact factor: 2.980